Cerus Corporation (CERS)
CERSNASDAQ-GMMedical/Dental Instruments
$1.95
-0.1200 (-5.80%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $393.81m
- P/E
- –
- EPS, last 4 quarters
- $-0.0300
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.47 to $3.47
- Average volume
- 1.84m
- Previous close
- $2.07
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $4.50, +130.8% from here
Earnings
next estimate $0.00000000Next report
Dec 2025
0.0%
Mar 2026
+66.7%
Jun 2026
–
Sep 2026
+100.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $64.58m | $59.89m | $63.30m | $64.02m |
| Gross profit | $36.58m | $34.13m | $35.39m | $36.57m |
| Operating income | -$641.0k | -$354.0k | -$1.86m | $383.0k |
| Net income | -$2.18m | -$1.64m | -$2.94m | -$550.0k |
Last four quarters: revenue $251.79m, margin -2.9%, free cash flow $494.0k
News
8 latest- Cerus: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Nov 3, 2026
- Cerus (CERS) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 3, 2026
- Cerus Q3 Earnings Call HighlightsMarketBeat · Nov 2, 2026
- Friday's ETF Movers: GXUS, ARKK BNK Invest · Jul 31, 2026
- Cerus Q2 Earnings Call HighlightsMarketBeat · Jul 30, 2026
- Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?Zacks · Jun 4, 2026
- BTIG Upgrades Cerus (CERS)Fintel · May 1, 2026
- Cerus (CERS) Q1 2026 Earnings TranscriptThe Motley Fool · Apr 30, 2026
The company
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- cerus.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.